Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ind-Swift LaboratoriesNSE:INDSWFTLAB -1.71%48 EV-to-EBITDA is 23.04 as of Aug. 07, 2026, which is 485% above its 10-year median of 3.94. GuruFocus rates NSE:INDSWFTLAB with a GF Score™ of 48/100 and a GF Value™ of ₹44.30 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 739 Drug Manufacturers companies, Ind-Swift Laboratories ranks worse than 71.85% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ind-Swift Laboratories's enterprise value is ₹15,161 Mil.
Ind-Swift Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹658 Mil. Therefore, Ind-Swift Laboratories's EV-to-EBITDA for today is 23.04.
The historical rank and industry rank for Ind-Swift Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:INDSWFTLAB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.36 Med: 3.94 Max: 27.11
Current: 23.04
During the past 13 years, the highest EV-to-EBITDA of Ind-Swift Laboratories was 27.11. The lowest was 0.36. And the median was 3.94.
NSE:INDSWFTLAB's EV-to-EBITDA is ranked worse than 71.85% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs NSE:INDSWFTLAB: 23.04
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ind-Swift Laboratories's PE Ratio (TTM) for today is calculated as:
Ind-Swift Laboratories's share price for today is ₹226.48.
Ind-Swift Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3.850.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ind-Swift Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ind-Swift Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ind-Swift Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ind-Swift Laboratories's EV-to-EBITDA falls into.
Ind-Swift Laboratories's current Enterprise Value is ₹15,161 Mil.
Ind-Swift Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹658 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ind-Swift Laboratories (NSE:INDSWFTLAB) has a EV-to-EBITDA of 23.04 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ind-Swift Laboratories. This is 485% above median its historical median of 3.94. Over the past decade, Ind-Swift Laboratories' EV-to-EBITDA has ranged from 0.36 to 27.11. According to the industry distribution chart, Ind-Swift Laboratories ranks #531 out of 739 companies in the Drug Manufacturers industry, placing it in the top 71.9%.
Is Ind-Swift Laboratories' EV-to-EBITDA too high?
Ind-Swift Laboratories' current EV-to-EBITDA of 23.04 is 485% above median its 10-year median of 3.94. Over the past 10 years, this metric has ranged from a low of 0.36 to a high of 27.11. The Drug Manufacturers industry median EV-to-EBITDA is 13.37. Ind-Swift Laboratories' value of 23.04 is 72.3% above this industry median. Based on the distribution chart, Ind-Swift Laboratories ranks #531 out of 739 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Ind-Swift Laboratories has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ind-Swift Laboratories' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Ind-Swift Laboratories ranks #531 out of 739 companies for EV-to-EBITDA. This places Ind-Swift Laboratories in the lower half of its industry. The industry median EV-to-EBITDA is 13.37. Ind-Swift Laboratories' value of 23.04 is 72.3% above this benchmark. Historically, Ind-Swift Laboratories' own EV-to-EBITDA has ranged from 0.36 to 27.11 over the past decade. While the company's 10-year median is 3.94 vs. the industry median of 13.37, Ind-Swift Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ind-Swift Laboratories's current EV-to-EBITDA of 23.04 is 72.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ind-Swift Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ind-Swift Laboratories's current EV-to-EBITDA is 23.04, which is 485% above median its own 10-year median of 3.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ind-Swift Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Ind-Swift Laboratories (NSE:INDSWFTLAB) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹44.30, compared to a current price of ₹226.48 — trading 411.2% above its estimated fair value. The current EV-to-EBITDA is 23.04, which is 485% above median its 10-year median of 3.94 and 72.3% above the Drug Manufacturers industry median of 13.37. Ind-Swift Laboratories' overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ind-Swift Laboratories (NSE:INDSWFTLAB), the current EV-to-EBITDA is 23.04 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ind-Swift Laboratories (NSE:INDSWFTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Ind-Swift Laboratories stock appears to be overvalued.
The current stock price of ₹226.48 is trading 411.2% above its estimated GF Value™ of ₹44.30.
GuruFocus considers Ind-Swift Laboratories to be Significantly Overvalued.
Key valuation signals for NSE:INDSWFTLAB:
EV-to-EBITDA: 23.04 (485% above median its 10-year median of 3.94)
GF Value™: ₹44.30 vs. price of ₹226.48 (411.2% above fair value)
Industry Position: 72.3% above the Drug Manufacturers median (#531 of 739)
No single metric tells the full story. See the NSE:INDSWFTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ind-Swift Laboratories Ltd is involved in manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company serves various therapeutic segments, including Cardiovascular health, Antihistamines, Antidiabetics, Antipsychotics, Parkinson's disease, Antineoplastics, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitors. It operates solely in the pharmaceutical products sector. Geographically, the company supplies both domestic and international markets, with the majority of its revenue coming from outside India.
48GF Score
Get the complete analysis for NSE:INDSWFTLAB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDSWFTLAB has been successfully added to your 
